Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

High serum IFN-alpha activity is a heritable risk factor for systemic lupus erythematosus.

Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK.

Genes Immun. 2007 Sep;8(6):492-502. Epub 2007 Jun 21.

2.

Association of endogenous anti-interferon-α autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus.

Morimoto AM, Flesher DT, Yang J, Wolslegel K, Wang X, Brady A, Abbas AR, Quarmby V, Wakshull E, Richardson B, Townsend MJ, Behrens TW.

Arthritis Rheum. 2011 Aug;63(8):2407-15. doi: 10.1002/art.30399.

3.

Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification.

Munroe ME, Lu R, Zhao YD, Fife DA, Robertson JM, Guthridge JM, Niewold TB, Tsokos GC, Keith MP, Harley JB, James JA.

Ann Rheum Dis. 2016 Nov;75(11):2014-2021. doi: 10.1136/annrheumdis-2015-208140. Epub 2016 Jan 25.

PMID:
27088255
4.

Association of the IRF5 risk haplotype with high serum interferon-alpha activity in systemic lupus erythematosus patients.

Niewold TB, Kelly JA, Flesch MH, Espinoza LR, Harley JB, Crow MK.

Arthritis Rheum. 2008 Aug;58(8):2481-7. doi: 10.1002/art.23613.

5.

Distinct autoantibody profiles in systemic lupus erythematosus patients are selectively associated with TLR7 and TLR9 upregulation.

Chauhan SK, Singh VV, Rai R, Rai M, Rai G.

J Clin Immunol. 2013 Jul;33(5):954-64. doi: 10.1007/s10875-013-9887-0. Epub 2013 Apr 7.

PMID:
23564191
6.

Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-α and serologic autoimmunity in lupus patients.

Robinson T, Kariuki SN, Franek BS, Kumabe M, Kumar AA, Badaracco M, Mikolaitis RA, Guerrero G, Utset TO, Drevlow BE, Zaacks LS, Grober JS, Cohen LM, Kirou KA, Crow MK, Jolly M, Niewold TB.

J Immunol. 2011 Aug 1;187(3):1298-303. doi: 10.4049/jimmunol.1100857. Epub 2011 Jun 24.

7.

Genetic variation at the IRF7/PHRF1 locus is associated with autoantibody profile and serum interferon-alpha activity in lupus patients.

Salloum R, Franek BS, Kariuki SN, Rhee L, Mikolaitis RA, Jolly M, Utset TO, Niewold TB.

Arthritis Rheum. 2010 Feb;62(2):553-61. doi: 10.1002/art.27182.

8.

Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin.

Wang H, Li T, Chen S, Gu Y, Ye S.

Arthritis Rheumatol. 2015 Dec;67(12):3190-200. doi: 10.1002/art.39296.

9.

Type I interferon and T helper 17 cells co-exist and co-regulate disease pathogenesis in lupus patients.

Biswas PS, Aggarwal R, Levesque MC, Maers K, Ramani K.

Int J Rheum Dis. 2015 Jul;18(6):646-53. doi: 10.1111/1756-185X.12636. Epub 2015 May 11.

PMID:
25960196
10.

Familial aggregation of high tumor necrosis factor alpha levels in systemic lupus erythematosus.

Mangale D, Kariuki SN, Chrabot BS, Kumabe M, Kelly JA, Harley JB, James JA, Sivils KL, Niewold TB.

Clin Dev Immunol. 2013;2013:267430. doi: 10.1155/2013/267430. Epub 2013 Sep 25.

11.

The autoimmune disease risk allele of UBE2L3 in African American patients with systemic lupus erythematosus: a recessive effect upon subphenotypes.

Agik S, Franek BS, Kumar AA, Kumabe M, Utset TO, Mikolaitis RA, Jolly M, Niewold TB.

J Rheumatol. 2012 Jan;39(1):73-8. doi: 10.3899/jrheum.110590. Epub 2011 Nov 1.

12.

Genetic ancestry, serum interferon-α activity, and autoantibodies in systemic lupus erythematosus.

Ko K, Franek BS, Marion M, Kaufman KM, Langefeld CD, Harley JB, Niewold TB.

J Rheumatol. 2012 Jun;39(6):1238-40. doi: 10.3899/jrheum.111467. Epub 2012 Apr 15.

13.

Increased binding of circulating systemic lupus erythematosus autoantibodies to recombinant interferon alpha 2b.

Khan WA, Qureshi JA.

APMIS. 2015 Dec;123(12):1016-24. doi: 10.1111/apm.12464.

PMID:
26547367
14.
15.

Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members.

Bruner BF, Guthridge JM, Lu R, Vidal G, Kelly JA, Robertson JM, Kamen DL, Gilkeson GS, Neas BR, Reichlin M, Scofield RH, Harley JB, James JA.

Arthritis Rheum. 2012 Nov;64(11):3677-86. doi: 10.1002/art.34651.

16.

Antibody against chromatin assembly factor-1 is a novel autoantibody specifically recognized in systemic lupus erythematosus.

Doe K, Nozawa K, Hiruma K, Yamada Y, Matsuki Y, Nakano S, Ogasawara M, Nakano H, Ikeda T, Ikegami T, Fujishiro M, Kawasaki M, Ikeda K, Amano H, Morimoto S, Ogawa H, Takamori K, Sekigawa I, Takasaki Y.

Lupus. 2014 Sep;23(10):1031-41. doi: 10.1177/0961203314536245. Epub 2014 May 16.

PMID:
24836587
17.

Interferon alpha as a primary pathogenic factor in human lupus.

Niewold TB.

J Interferon Cytokine Res. 2011 Dec;31(12):887-92. doi: 10.1089/jir.2011.0071. Epub 2011 Sep 16. Review.

18.

Increased serum β2-microglobulin is associated with clinical and immunological markers of disease activity in systemic lupus erythematosus patients.

Hermansen ML, Hummelshøj L, Lundsgaard D, Hornum L, Keller P, Fleckner J, Fox B, Poulsen LK, Jacobsen S.

Lupus. 2012 Sep;21(10):1098-104. doi: 10.1177/0961203312447668. Epub 2012 May 10.

PMID:
22577117
19.

Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus.

Jolly M, Francis S, Aggarwal R, Mikolaitis RA, Niewold TB, Chubinskaya S, Block JA, Scanzello C, Sequeira W.

Lupus. 2014 Aug;23(9):881-8. doi: 10.1177/0961203314530793. Epub 2014 Apr 30.

PMID:
24786785
20.

Clinical and serological manifestations associated with interferon-α levels in childhood-onset systemic lupus erythematosus.

Postal M, Sinicato NA, Peliçari KO, Marini R, Lavras Costallat LT, Appenzeller S.

Clinics (Sao Paulo). 2012;67(2):157-62.

Supplemental Content

Support Center